1. Scrip
  2. >>Focus On Asia

Here Comes Sun’s US Cost-Saving Gleevec Generic

 
• By Anju Ghangurde

India’s Sun Pharma has launched its generic version of Novartis' blockbuster anticancer Gleevec in the US at savings of around 30%, putting the spotlight on the specialty segment which is probably, for the first time, witnessing genericization of such a high cost therapy.

Sun Pharmaceutical Industries Ltd.’s generic version of Novartis AG‘s leukemia drug Gleevec (imatinib mesylate) has reached the market in the US at a roughly 30% discount to the original product.

Manish Jain, a founder partner of SageOne Investment Advisors, told PharmAsia News’s sister publication Scrip Intelligence that he expected Sun to rake in sales of around $450m on a "conservative basis" from its generic Gleevec during the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.